Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GB-0669 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GB-0669 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 0669 (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; First in man
  • Sponsors Generate Biomedicines

Most Recent Events

  • 03 Jul 2025 Status changed from recruiting to completed.
  • 09 Jan 2025 According to a Generate Biomedicines media release, results from this study were presented at IDWeek 2024.
  • 04 Jan 2024 According to a Generate Biomedicines Media Release, safety has been shown for the first four of five planned cohorts, including the putative recommended dose; analysis of key biomarkers is ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top